Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity.

Xizi HuShoiab M BukhariCarly TymmKieran AdamShalom LerrerBrian S HenickRobert J WinchesterAdam Mor

Published in: Journal for immunotherapy of cancer (2024)

These findings suggest that IL-25/IL-17RA may serve as an additional target when treating ICI-responsive tumors, allowing for better tumor control while suppressing immune-related toxicities.

Keyphrases

rheumatoid arthritis
dna damage
signaling pathway
ankylosing spondylitis
cancer therapy
systemic sclerosis